WASHINGTON, Jan. 13, 2020 /PRNewswire/ -- Danaher
Corporation (NYSE: DHR) (the "Company") announced today that its
President and Chief Executive Officer, Thomas P. Joyce, Jr., will comment tomorrow on
the Company's fourth quarter 2019 performance in a presentation at
the J.P. Morgan Healthcare Conference in San Francisco, California at 8:00 a.m. PT.
Mr. Joyce will communicate that fourth quarter 2019 core revenue
growth is expected to be above the Company's previously announced
guidance, driven by better performance in its Life Sciences and
Diagnostics segments. Mr. Joyce will also comment that adjusted
diluted net earnings per share is expected to be at or above the
high-end of the Company's previously announced guidance.
As previously announced, Danaher will hold its quarterly
earnings conference call for the fourth quarter and year-end 2019
on Thursday, January 30, 2020 at
8:00 a.m. ET.
ABOUT DANAHER
Danaher is a global science and
technology innovator committed to helping its customers solve
complex challenges and improving quality of life around the world.
Its family of world class brands has leadership positions in the
demanding and attractive health care, environmental and applied
end-markets. With more than 20 operating companies, Danaher's
globally diverse team of more than 60,000 associates is united by a
common culture and operating system, the Danaher Business System,
and its Shared Purpose, Helping Realize Life's Potential.
For more information, please visit www.danaher.com.
FORWARD LOOKING STATEMENTS
Statements in this release
that are not strictly historical, including the statements
regarding the Company's anticipated financial performance for the
fourth quarter of 2019 and any other statements regarding events or
developments that we believe or anticipate will or may occur in the
future are "forward-looking" statements within the meaning of the
federal securities laws. There are a number of important factors
that could cause actual results, developments and business
decisions to differ materially from those suggested or indicated by
such forward-looking statements and you should not place undue
reliance on any such forward-looking statements. These factors
include, among other things, deterioration of or instability in the
economy, the markets we serve and the financial markets,
developments and uncertainties in U.S. policy stemming from the
U.S. administration, such as changes in U.S. trade and tariff
policies and the reaction of other countries thereto, contractions
or growth rates and cyclicality of markets we serve, competition,
our ability to develop and successfully market new products and
technologies and expand into new markets, the potential for
improper conduct by our employees, agents or business partners, our
compliance with applicable laws and regulations (including
regulations relating to medical devices and the health care
industry), the results of our clinical trials and perceptions
thereof, our ability to effectively address cost reductions and
other changes in the health care industry, our ability to
successfully identify and consummate appropriate acquisitions and
strategic investments and successfully complete divestitures and
other dispositions, our ability to integrate the businesses we
acquire and achieve the anticipated benefits of such acquisitions,
contingent liabilities relating to acquisitions, investments and
divestitures (including tax-related and other contingent
liabilities relating to past and future IPOs, split-offs or
spin-offs), security breaches or other disruptions of our
information technology systems or violations of data privacy laws,
the impact of our restructuring activities on our ability to grow,
risks relating to potential impairment of goodwill and other
intangible assets, currency exchange rates, tax audits and changes
in our tax rate and income tax liabilities, changes in tax laws
applicable to multinational companies, litigation and other
contingent liabilities including intellectual property and
environmental, health and safety matters, the rights of
the United States government to
use, disclose and license certain intellectual property we license
if we fail to commercialize it, risks relating to product, service
or software defects, product liability and recalls, risks relating
to product manufacturing, the impact of our debt obligations on our
operations and liquidity, our relationships with and the
performance of our channel partners, uncertainties relating to
collaboration arrangements with third-parties, commodity costs and
surcharges, our ability to adjust purchases and manufacturing
capacity to reflect market conditions, reliance on sole sources of
supply, the impact of deregulation on demand for our products and
services, labor matters, international economic, political, legal,
compliance and business factors (including the impact of the
United Kingdom's decision to leave
the EU and uncertainty relating to the terms and timing of such
separation), disruptions relating to man-made and natural disasters
and pension plan costs. Additional information regarding the
factors that may cause actual results to differ materially from
these forward-looking statements is available in our SEC filings,
including our 2018 Annual Report on Form 10-K and Quarterly Reports
on Form 10-Q for each of the first, second and third quarters of
2019. These forward-looking statements speak only as of the date of
this release and except to the extent required by applicable law,
the Company does not assume any obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events and developments or otherwise.
View original
content:http://www.prnewswire.com/news-releases/danaher-ceo-to-comment-on-financial-performance-300986028.html
SOURCE Danaher Corporation